x Health Men's Health Children's Health Nutrition and Wellness Reproductive Health Health & Science Digital News Videos Opinions Cartoons Education E-Paper Lifestyle & Entertainment Nairobian Entertainment Eve Woman Travelog TV Stations KTN Home KTN News BTV KTN Farmers TV Radio Stations Radio Maisha Spice FM Vybez Radio Enterprise BULK SMS E-Learning Digger Classified The Standard Group Corporate Contact Us Rate Card Vacancies DCX O.M Portal Corporate Email RMS
Login ×
BTV
VAS
DCX
RMS

New HIV testing kit approved by WHO

Health & Science - By Jeckonia Otieno | May 4th 2019 at 04:11:25 GMT +0300

The first ever point-of-care test for HIV viral load has been pre-approved by the World Health Organisation (WHO).

m-PIMA, the world's first point-of-care viral load diagnostic test, has received Prequalification approval (WHO PQ). This follows the CE Marking which it received in December 2018. It was developed by Abott.

"m-PIMA HIV-1/2 VL is the only truly portable molecular point-of-care test designed specifically for use in resource-limited settings such as in sub-Saharan Africa," said Damian Halloran, vice president, Infectious Disease – Emerging Markets, Rapid Diagnostics, Abbott.

The use of m-Pima is expected to ease the hassle of viral load testing especially in areas where it would take long to access testing equipment.

Halloran said, "With WHO PQ, global funders and ministries of health can now confidently expand access to viral load testing, reaching more people who need the test, with the most compact and efficient point-of-care HIV diagnostic platform available anywhere in the world today."

To provide the most effective HIV treatment and care, the WHO recommends that everyone receiving antiretroviral therapy (ART) undergoes a viral load test at 6 months and 12 months, and annually thereafter if the individual is stable on ART.

Viral load testing is the gold standard for monitoring ART treatment failure. Unfortunately, very few people in resource-limited settings, such as select countries in sub-Saharan Africa, Asia and Latin America, have access to the necessary level of care.

The platform is portable so it can be brought into the most remote locations. It’s easy to use, deployable at the point of care and designed to measure viral load in under 70 minutes, while the patient is still present.

This allows people to receive results during the same visit and enables immediate treatment decisions, thereby reducing the number of people lost to follow-up.

The test’s quick turnaround time is particularly valuable for monitoring the viral load of HIV-positive pregnant women and in cases of suspected HIV treatment failure.

The m-PIMA HIV-1/2 VL is part of Abbott’s comprehensive portfolio of diagnostic solutions for HIV screening, monitoring and viral load management.

From the core lab to the point of care, Abbott provides critical tools to help healthcare providers make informed treatment decisions for people living with HIV.

WHO Prequalification (PQ) aims to ensure that diagnostics, medicines, vaccines and immunization-related equipment and devices for high burden diseases meet global standards of quality, safety and efficacy, to optimize the use of health resources and improve health outcomes.

Be The First To Comment

Top Stories

Covid-19 jab: Will the poor have a fair shot?
Health & Science - By Dominic Omondi


Relief as nurses end strike
Health & Science - By Graham Kajilwa


My wife’s genes are killing our children
Health & Science - By Lydiah Nyawira


Vaccine will be rolled out in June, says State
Health & Science - By Graham Kajilwa


Why Kenyans might have to wait until next year for elusive Covid-19 vaccine
Health & Science - By Mercy Kahenda


Covid-19: Two dead as 280 test positive
Health & Science - By Mercy Asamba


Tanzania changes tune, issues covid-19 rules
Health & Science - By Jennifer Anyango


FDA staff: Johnson & Johnson's one-shot Covid-19 vaccine effective, safe
Health & Science - By Reuters


Kenya records first case of rare mad cow disease in human
Health & Science - By Gatonye Gathura


Fears brain-swelling Nipah virus with up to 75% death rate 'may become next pandemic'
Health & Science - By Mirror


Latest Stories

Relief as nurses end strike
Health & Science - By Graham Kajilwa


Pfizer vaccine found 94% effective in real world
Health & Science - By Reuters


New coronavirus variant identified in New York: researchers
Health & Science - By Reuters


Covid-19 jab: Will the poor have a fair shot?
Health & Science - By Dominic Omondi


FDA staff: Johnson & Johnson's one-shot Covid-19 vaccine effective, safe
Health & Science - By Reuters


Covid-19: what happens if some countries don’t vaccinate?
Health & Science - By WEF


Tanzania changes tune, issues covid-19 rules
Health & Science - By Jennifer Anyango


WHO to compensate for serious jab side effects
Health & Science - By Xinhua


Covid-19: Two dead as 280 test positive
Health & Science - By Mercy Asamba


What you need to know about the coronavirus right now
Health & Science - By Reuters


//

Stay Ahead!

Access premium content only available
to our subscribers.

Or Login With Your Standard Account
Support independent journalism
×
Create An Account
Support independent journalism
I have an account Log in
Reset Password
Support independent journalism
Log in